No results for ‘’
Aarti Drugs Ltd
₹428.50
(1.95%)
Tue, 22 Sept 2026, 03:34 pm
Health Technology
Pharmaceuticals: Major
24.5KAarti Drugs Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 9.89 | 7.11 | 4.47 | 2.79 | 4.32 | 6.52 | 5.71 | 3.83 | 5.25 | 20.43 | 16.01 | 16.78 | 14.52 | 16.83 | 8.33 | 23.09 | 19.37 | 18.81 | 23.27 | 18.44 |
| Price to book ratio | 1.18 | 0.73 | 0.55 | 0.36 | 0.82 | 0.95 | 0.70 | 0.84 | 1.27 | 5.12 | 3.08 | 3.43 | 2.62 | 2.78 | 1.81 | 7.09 | 3.83 | 2.62 | 3.11 | 2.27 |
| Price to sales ratio | 0.52 | 0.34 | 0.20 | 0.12 | 0.25 | 0.31 | 0.19 | 0.21 | 0.33 | 1.44 | 0.97 | 1.15 | 0.96 | 0.97 | 0.65 | 3.01 | 1.60 | 1.15 | 1.58 | 1.30 |
| Price to cash flow ratio | 0 | 5.46 | 4.14 | 1.36 | 2.98 | 43.78 | 10.12 | 3.73 | 5.04 | 23.89 | 12.19 | 9.89 | 33.37 | 14.45 | 5.40 | 47.11 | 76.17 | 31.69 | 12.08 | 13.89 |
| Enterprise value | 328Cr | 306Cr | 289Cr | 243Cr | 306Cr | 417Cr | 416Cr | 491Cr | 693Cr | 2023Cr | 1579Cr | 1848Cr | 1737Cr | 2012Cr | 1560Cr | 6816Cr | 4493Cr | 3728Cr | 4544Cr | 3709Cr |
| Enterprise value to EBITDA ratio | 8.78 | 7.35 | 6.41 | 3.76 | 3.68 | 5.96 | 5.58 | 4.07 | 4.73 | 11.84 | 8.94 | 9.51 | 8.52 | 9.44 | 5.82 | 15.35 | 13.33 | 11.83 | 14.20 | 12.94 |
| Debt to equity ratio | 2.16 | 1.99 | 1.95 | 1.56 | 1.29 | 1.64 | 1.69 | 1.54 | 1.51 | 1.45 | 1.35 | 1.20 | 1.20 | 0.93 | 0.60 | 0.38 | 0.52 | 0.51 | 0.44 | 0.45 |
| Return on equity % | 16.30 | 14.64 | 12.98 | 13.59 | 20.73 | 15.35 | 12.72 | 23.56 | 26.52 | 27.64 | 20.65 | 21.60 | 19.24 | 17.97 | 23.65 | 35.81 | 21.03 | 14.92 | 13.86 | 12.69 |
Aarti Drugs Ltd Enterprise Value
The Aarti Drugs Ltd Enterprise Value is a key financial metric used by investors to evaluate Aarti Drugs Ltd's valuation, profitability, and overall financial performance. Tracking the Aarti Drugs Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Aarti Drugs Ltd (NSE: AARTIDRUGS, BSE: 524348) is currently trading at ₹428.50, with a market capitalization of ₹3909.55Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Aarti Drugs Ltd Enterprise Value is essential for fundamental analysis.
Aarti Drugs Ltd Enterprise Value Current Value
The current Aarti Drugs Ltd Enterprise Value stands at 3709Cr.
The Aarti Drugs Ltd Enterprise Value has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Aarti Drugs Ltd Enterprise Value Historical Trend
The Aarti Drugs Ltd Enterprise Value has shown the following historical trend:
- 2024: 3709Cr
- 2023: 4544Cr
- 2022: 3728Cr
- 2021: 4493Cr
- 2020: 6816Cr
The decline in Aarti Drugs Ltd Enterprise Value indicates improving financial efficiency or better earnings growth.
What Aarti Drugs Ltd Enterprise Value Indicates for Investors
The Aarti Drugs Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Aarti Drugs Ltd.
Aarti Drugs Ltd Enterprise Value Analysis Summary
The Aarti Drugs Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Aarti Drugs Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Aarti Drugs Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.